PCM
PRVB

Penserra Capital Management’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Penserra Capital Management’s Portfolio PRVB Stock Details PRVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,450
Closed -$9K – 1617
2021
Q3 		$9K Buy
1,450
+5
+0.3% +$32 ﹤0.01% 1375
2021
Q2 		$12K Buy
1,445
+10
+0.7% +$81 ﹤0.01% 1265
2021
Q1 		$15K Buy
1,435
+115
+9% +$1.62K ﹤0.01% 997
2020
Q4 		$22K Buy
+1,320
New +$19.8K ﹤0.01% 841

Other funds holding PRVB

SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
DCM
DG Capital Management New York $326M AUM 39.67% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Penserra Capital Management's PRVB Position: Q4 2021 in Review

Penserra Capital Management sold out of Provention Bio, Inc. Common Stock (PRVB) in Q4 2021, closing a stake of 1,450 shares — an estimated $9K sold.

Penserra Capital Management first reported a position in PRVB in Q4 2020 and held it in 4 quarters. The position peaked at $22K in Q4 2020. 112 funds tracked by Wall St. Rank hold PRVB as of Q4 2021.

  • Penserra Capital Management reported no remaining Provention Bio, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Penserra Capital Management sold 1,450 Provention Bio, Inc. Common Stock shares in Q4 2021, an estimated $9K.
  • Penserra Capital Management first reported a position in Provention Bio, Inc. Common Stock in Q4 2020 and held it in 4 quarters.
  • Penserra Capital Management's Provention Bio, Inc. Common Stock position peaked at $22K in Q4 2020.
  • 112 funds tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q4 2021.

Based on Penserra Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.